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Abstract
Background: In order to provide a cost-effective tool to analyse pharmacogenetic markers in
malaria treatment, DNA microarray technology was compared with sequencing of polymerase
chain reaction (PCR) fragments to detect single nucleotide polymorphisms (SNPs) in a larger
number of samples.
Methods: The microarray was developed to affordably generate SNP data of genes encoding the
human cytochrome P450 enzyme family (CYP) and N-acetyltransferase-2 (NAT2) involved in anti-
malarial drug metabolisms and with known polymorphisms, i.e. CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NAT2.
Results: For some SNPs, i.e. CYP2A6*2, CYP2B6*5, CYP2C8*3, CYP2C9*3/*5, CYP2C19*3,
CYP2D6*4 and NAT2*6/*7/*14, agreement between both techniques ranged from substantial to
almost perfect (kappa index between 0.61 and 1.00), whilst for other SNPs a large variability from
slight to substantial agreement (kappa index between 0.39 and 1.00) was found, e.g. CYP2D6*17
(2850C>T), CYP3A4*1B and CYP3A5*3.
Conclusion: The major limit of the microarray technology for this purpose was lack of robustness
and with a large number of missing data or with incorrect specificity.
Background
Drug action depends on how drugs are metabolized and
differences in activity of metabolizing enzymes can signif-
icantly contribute to the efficacy of drugs [1,2]. This might
also be true for drugs given to treat malaria. The objective
was to analyse single nucleotide polymorphisms (SNPs)
in genes encoding enzymes implicated in metabolizing
anti-malarial drugs in order to determine the contribution
of these enzymes to the pharmacokinetics of the specific
drugs. There are many methods available for the detection
of SNPs (for review see [3,4]). These methods are either
based on allele-specific hybridization or on primer exten-
sion reaction. Many of these techniques are time consum-
ing, expensive and/or not suitable for use in resource-poor
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based [5] technique to detect SNPs associated with drug
resistance in malaria parasites in a larger sample size has
been developed and successfully used. To test whether this
system also could be used for SNP determination in
metabolizing enzyme genes, microarray determined SNPs
were compared with sequencing. For this, a microarray
was developed to affordably generate SNP data on genes
encoding the human cytochrome P450 enzyme family
(CYP) and N-acetyltransferase-2 (NAT2) involved in anti-
malarial drug metabolisms. The performance of this
microarray had to be determined subsequently. The
microarray was designed to analyse enzyme genes with
known polymorphisms such as CYP2A6 and CYP2B6 for
the artemisinins, CYP2C8 for amodiaquine, chloroquine
and dapsone, CYP2C9 and NAT2 for dapsone and sul-
phamethoxazole, CYP2C19 for dapsone and proguanil,
CYP2D6 for chloroquine and halofantrine, CYP3A4 for
the artemisinins, chloroquine, dapsone, halofantrine,
lumefantrine, mefloquine, primaquine and quinine, and
CYP3A5 for artemether, β-arteether, chloroquine, meflo-
quine, quinine and sulphadoxine [6-29]. For certain anti-
malarial drugs (piperaquine, pyrimethamine and pyron-
aridine) the metabolic pathway is yet not well known,
while others (atovaquone and doxycycline) are barely
metabolized at all [30-35].
Methods
Study population
During an in vivo drug efficacy study in patients with
uncomplicated malaria of all age, venous blood samples
(anticoagulated using EDTA) were obtained after
informed consent from 125 patients in Northern and
Western Cambodia (64 in 2007 at Phnom Dék Health
Centre, Rovieng district, Preah Vihear province, and 61 in
2008 at Pramoy Health Centre, Veal Veng district, Pursat
province) and 149 patients in Central Tanzania (in 2008
at Kibaoni Health Centre, Kilombero district, Morogoro
region).
Sequencing
Genomic DNA was extracted from 200 μl whole blood
using the QIAamp 96 DNA Blood Kit (QIAGEN GmbH,
Germany) according to the manufacturer's instructions.
Target sequences in cyp and nat2 genes of these samples
were amplified using PCR. The PCR primers used are
listed in Table 1. The amplified regions contained SNPs
which are known to alter the function of enzymes
involved in the metabolism of anti-malarial drugs (for tar-
get loci and effect of the SNP see Table 1). The PCR master
mix contained 1 × reaction buffer B (Solis BioDyne, Esto-
nia), 1 × solution S (Solis BioDyne, Estonia), 10 μM of
each primer in 1 × Tris-EDTA (see Table 1, Operon Bio-
technologies GmbH, Germany), MgCl2 (according to
Table 1, Solis BioDyne, Estonia), 2 mM of each dNTP in
Tris-HCl 10 mM, pH 7.4 (GE Healthcare, Switzerland)
and 2 U FIREPol DNA polymerase (Solis BioDyne, Esto-
nia). 1 μl of extracted DNA was mixed with 24 μl of PCR
master mix. The PCR protocol was 3 min at 96°C fol-
lowed by 40 cycles (30 sec at 96°C, 1 min 30 sec at 56-
64°C according to Table 1 and 1 min 30 sec at 72°C) with
a final elongation for 10 min at 72°C. PCR products were
purified and sequenced by Macrogen (Macrogen Ltd.,
Korea). ABI Prism AutoAssembler version 1.4.0 (Applied
Biosystems) was used for assembly and analysis of
sequences. The genotype of each patient was then assessed
visually. Aliquots of the same PCR products were used for
primer extension and microarray analysis.
Patient selection for DNA microarray validation
Of 274 patients from Cambodia and Tanzania, 96 were
selected (i.e. to fit 96-well plate) for validation of the
microarray. Samples were selected by the number of suc-
cessfully sequenced SNPs and then their ID number. For
all 96 selected samples at least 16 out of 18 SNPs have
been successfully sequenced.
Extension control and elimination of non-incorporated 
nucleotides
As extension control for the microarray, amplified nested
PCR product from the Plasmodium falciparum chloroquine
resistance transporter gene (pfcrt) from strains 3D7
(wildtype at loci pfcrt76 and pfcrt97) and K1 (mutation at
locus pfcrt76 and wild-type at pfcrt97) were mixed at a
ratio of 55%:45%. Primers and PCR conditions have been
described elsewhere [5].
To eliminate non-incorporated nucleotides prior to
primer extension, all nested PCR products of one blood
sample were pooled and 10 μl of the pooled PCR products
and 0.5 μl of the extension control mix were digested with
8 U shrimp alkaline phosphatase (SAP) and 4 μl 10 × SAP
buffer (both Amersham Biosciences, Freiburg, Germany)
in a reaction volume of 48 μl for 1 h at 37°C. SAP was
inactivated by incubating samples for 15 min at 90°C.
Primer extension and denaturation
Since the microarray scanner used only supported dual-
fluorescence measures simultaneously and because of the
large similarity of the cyp genes, a strategy of three parallel
reactions with different primer and dye combinations had
to be applied. Different extension primer mixes (I, II and
III) were prepared according to Table 2, each with a total
volume of 320 μl containing the corresponding primers
(62.5 nM final concentration of each primer, Operon Bio-
technologies GmbH, Germany) diluted in 1 × Tris-EDTA
(TE). Afterwards, three extension mixes (I, II and III) were
prepared (final volume of 8 μl) containing 2 U of HOT
TERMIPol® DNA Polymerase (Solis BioDyne, Estonia), 1.8Page 2 of 9
(page number not for citation purposes)
Malaria Journal 2009, 8:285 http://www.malariajournal.com/content/8/1/285μl of 10 × Reaction Buffer C (Solis BioDyne, Estonia), 2.5
mM MgCl2, and 0.625 μM of the corresponding Cy3- and
Cy5-labeled ddNTPs (Perkin Elmer, Schwerzenbach, Swit-
zerland); ddNTP mixes are listed in Table 3. Then, 12 μl
SAP digested PCR product of each patient were mixed
with 8 μl of the extension mix I, II or III, respectively. The
following primer extension protocol was used: 1 min at
94°C followed by 40 cycles of 10 sec at 94°C followed by
40 sec at 50°C. The three mixes of each patient were then
pooled again in a 96 well plate and mixed with 10 μl of
the hybridization buffer. The hybridization buffer con-
tained 37.5 μM EDTA pH 8.0, 7 pM of two differently
labelled positive hybridization controls 5'-GCCTCCACG-
CACGTTGTGATATGTA- [Cy3]-3' and 5'- CTGTGACAGAG
CCAACACGCAGTCT- [Cy5]-5' (Operon Biotechnologies
GmbH, Germany), and 3% sodium dodecyl sulphate
Table 1: Primers used to amplify target sequences in cytochromes P450 isoenzymes and N-acetyltransferase 2 genes, MgCl2 [μl] for 
the master mix and annealing temperature [°C] used to amplify target sequence in cytochromes P450 isoenzyme genes and N-
acetyltransferase 2 genes.
SNP primer Sequence MgCl2 [μl] T [°C]
CYP2A6*2 (479T>A, L160H) forward
reverse
5'-TCTCTCTCTCTACCTCGACAT-3'
5'-GTTCCTCGTCCTGGGTGTT-3'
3 64
CYP2B6*5 (1459C>T, R487C) forward
reverse
5'-CCAGAAGACATCGATCTGAC-3'
5'-TCTCTCAGAGGCAGGAAGTT-3'
2 64
CYP2B6*6 (516G>T, Q172H) forward
reverse
5'-TGAGTGATGGCAGACAATCACA-3'
5'-CAAGTTGAGCATCTTCAGGAACT-3'
2 64
CYP2C8*3 (416G>A, R139K) forward
reverse
5'-CTAAAGGACTTGGTAGGTGCA-3'
5'-CAGGATGCGCAATGAAGACC-3'
2 64
CYP2C9*3/*5 (1075A>C, I359L/1080C>G, D360E) forward
reverse
5'-CTGGTTTATGGCAGTTACACATT-3'
5'-GAGAAAGTCCAGTTAAACTGCC-3'
2 64
CYP2C19*3 (636G>A, W212X) forward
reverse
5'-GGGAATTCATAGGTAAGATATTA-3'
5'-GGAGTGATATAAGCACGCTTTG-3'
2 64
CYP2D6*4 (1846G>A, splicing defect) forward
reverse
5'-CCGCCTTCGCCAACCACT-3'
5'-CCCTGCAGAGACTCCTCGGT-3'
2 64
CYP2D6*10 (100C>T, P34S) forward
reverse
5'-CCCATTTGGTAGTGAGGCAGGT-3'
5'-CCCCTTCTCAGCCTGGCTTCTTG-3'
2 64
CYP2D6*10 (4180G>C, S486T) forward
reverse
5'-AGCCACCATGGTGTCTTTGCT-3'
5'-TTGCCCTGAGGAGGATGATC-3'
2 64
CYP2D6*17 (1023C>T, T107I) forward
reverse
5'-CGCGAGGCGCTGGTGACCAA-3'
5'-CCAGCTCGGACTACGGTCATCAC-3'
2 64
CYP2D6*17 (2850C>T, R296C) forward
reverse
5'-GACTCTGTACCTCCTATCCACGTCA-3'
5'-TCCCTCGGCCCCTGCACTGTTT-3'
2 64
CYP3A4*1B (-392A>G) forward
reverse
5'-CTCACCTCTGTTCAGGGAAAC-3'
5'-ATGGCCAAGTCTGGGATGAG-3'
2 64
CYP3A5*3 (6986A>G, splicing defect) forward
reverse
5'-TGGAGAGTGGCATAGGAGATAC-3'
5'-CCATACCCCTAGTTGTACGACACA-3'
2.5 64
NAT2*5/*6/*7/*14 
(341T>C, I114T/590G>A, R197Q/857G>A, G286E/
191G>A, R64Q)
forward
reverse
5'-GGGATCATGGACATTGAAGCATATT-3'
5'-ACGTGAGGGTAGAGAGGATATCTG-3'
2 64
Primers highlighted in bold were used for sequencing. SNP positions are indicated in brackets; they were obtained from the Home Page of the 
Human Cytochrome P450 (CYP) Allele Nomenclature Committee [41], and the Consensus Human Arylamine N-Acetyltransferase Gene 
Nomenclature [44].Page 3 of 9
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immediately chilled on ice for 2 min.
Microarray production and microarray hybridization
Aldehyde-activated ArrayIt® SuperAldehyde 2 glass slides
with SuperMask™ 16 (EBN European Biotech Network,
Dolembreux, Belgium) were used. Oligonucleotides
(Operon Biotechnologies GmbH, Germany) correspond-
ing to the antisense DNA of the extension primers, exten-
sion controls (Table 2) and positive hybridization
controls were spotted onto the microarrays in triplicate.
The spotting was done by the DNA Array Facility of the
Center for Integrative Genomics, University of Lausanne,
Switzerland, using solutions of 50 μM oligonucleotide in
180 mM phosphate buffer (pH 8.0). All oligonucleotides
had a C7-aminolinker attached to the 3' end. Anchor oli-
gonucleotides prelabeled with Cy3 and Cy5 and four oli-
gonucleotides with a random sequence were added as
positive and negative controls, respectively. Of the pooled
and denatured primer extension reaction mixture 35 μl
were transferred to one well of the microarray, and 6 μl 20
× Standard Saline Citrate (SSC) were added. In each well,
representing a single microarray, DNA from one patient
was hybridized. Hybridization was carried out in a humid
chamber at 50°C for 90 min. After hybridization, the slide
was washed at room temperature in 2 × SSC with 0.2%
SDS for 10 min, followed by a wash with 2 × SSC for 10
min, and a final wash with 2 × SSC plus 2% ethanol for 2
min. These three steps represent the first wash step. Slides
were dried with compressed air.
Data acquisition
Microarrays were scanned at 635 nm and 532 nm using an
Axon 4100A fluorescence scanner (Bucher Biotec AG,
Basel, Switzerland). After the first scan slides were washed
and scanned again and after each wash, Cy3 and Cy5
images were acquired and analysed using the Axon Gene-
Pix Pro software (version 6.0). An in house developed perl
script based on Kestler's statistics module [36] was used to
call SNPs based on probe signal intensities. The script cal-
culates receiver operating characteristic (ROC) curves
using signal intensity values from the set of positive and
negative controls for each hybridization. Hybridization
specific thresholds that maximize both sensitivity and
specificity were then used to make SNP calls.
Table 2: Extension primers of three parallel mixes.
SNP Primer Mix
CYP2C8*3.1 5'-GGAATTTTGGGATGGGGAAGA-3' I
CYP2A6*2 5'-GCTTCCTCATCGACGCCC-3' I
CYP2D6*4 5'-CCGCATCTCCCACCCCCA-3' I
CYP2D6*10 (100C>T) 5'-ACGCTGGGCTGCACGCTAC-3' I
CYP2D6*17 (2859C>T) 5'-AGCTTCAATGATGAGAACCTG-3' I
CYP2D6*17 (1023C>T) 5'-CCCGAAACCCAGGATCTGG-3' I
CYP3A5*3 5'-TGGTCCAAACAGGGAAGAGATA-3' I
CYP3A4*1B 5'-CATAAAATCTATTAAATCGCCTCTCTC-3' I
E. CYP2C9*3 5'-TGCACGAGGTCCAGAGATAC-3' II
E. CYP2C9*5 5'-CAGGCTGGTGGGGAGAAG-3' II
E. CYP2B6*6 (516G>T) 5'-AGATGATGTTGGCGGTAATGGA-3' II
E. CYP2D6*10 (4180G>C) 5'-GTGTCTTTGCTTTCCTGGTGA-3' II
pfcrt76 5'-TTTGTTTAAAGTTCTTTTAGCAAAAATT-3' II
pfcrt97 5'-GTTTTGTAACATCCGAAACTCA-3' II
NAT2*7 5'-GTGCCCAAACCTGGTGATG-3' III
NAT2*14 5'-TTGATCACATTGTAAGAAGAAACC-3' III
CYP2C19*3 5'-AGGATTGTAAGCACCCCCTG-3' III
CYP2B6*5 5'-TACCCCCAACATACCAGATC-3' III
NAT2*5 5'-CTTCTCCTGCAGGTGACCA-3' III
NAT2*6 5'-TATACTTATTTACGCTTGAACCTC-3' III
Table 3: Labelled ddNTPs used for the three parallel extension 
mixes.
ddNTP and label Mix
ddATP Cy3 I
ddCTP Cy3
ddGTP Cy5
ddUTP Cy5
ddATP Cy5 II
ddCTP Cy3
ddGTP Cy5
ddUTP Cy3
ddATP Cy3 III
ddCTP Cy5
ddGTP Cy5
ddUTP Cy5Page 4 of 9
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Table 4: Comparison of SNP data acquired either by sequencing or DNA microarray technology.
1st wash 2nd wash
SNP Country κ n % κ n % Agreement
CYP2A6*2 Cambodia 0.87 24 88.9 0.92 19 70.4 Substantial to almost
Tanzania 0.83 58 82.9 0.61 53 75.7 perfect
CYP2B6*5 Cambodia 0.94 27 100.0 0.94 27 100.0 Almost perfect
Tanzania 0.92 67 95.7 0.86 67 95.7
CYP2B6*6 Cambodia 0.42 26 96.3 0.42 27 100.0 Fair to moderate
Tanzania 0.35 63 90.0 0.40 59 84.3
CYP2C8*3 Cambodia 0.97 20 74.1 1.00 20 74.1 Substantial to almost
Tanzania 0.90 39 55.7 0.79 38 54.3 perfect
CYP2C9*3 Cambodia 0.92 26 96.3 0.94 26 96.3 Almost perfect
Tanzania 0.90 67 95.7 0.82 64 91.4
CYP2C9*5 Cambodia 0.98 27 100.0 1.00 27 100.0 Almost perfect
Tanzania 0.93 67 95.7 0.86 70 100.0
CYP2C19*3 Cambodia 1.00 27 100.0 1.00 26 96.3 Almost perfect
Tanzania 0.90 97 95.7 0.83 66 94.3
CYP2D6*4 Cambodia 0.98 26 96.3 1.00 26 96.3 Almost perfect
Tanzania 0.91 63 90.0 0.88 65 92.9
CYP2D6*10 (100C>T) Cambodia 0.59 24 88.9 0.64 20 74.1 Moderate to substantial
Tanzania 0.72 31 44.3 0.76 27 38.6
CYP2D6*10 (4180G>C) Cambodia 0,40 21 77.8 0.50 17 63.0 Fair to moderate
Tanzania 0.45 45 64.3 0.51 38 54.3
CYP2D6*17 (1023C>T) Cambodia 0.86 19 70.4 1.00 6 22.2 Moderate to almost
Tanzania 0.59 37 52.9 0.49 37 52.9 perfect
CYP2D6*17 (2850C>T) Cambodia 0.29 7 25.9 0.20 6 22.2 Slight to substantial
Tanzania 0.66 20 28.6 0.59 21 30.0
CYP3A4*1B Cambodia 0.00 6 22.2 0.00 5 18.5 Slight to substantial
Tanzania 0.76 23 32.9 0.69 22 31.4
CYP3A5*3 Cambodia 0.39 21 77.8 0.42 17 63 Fair to substantial
Tanzania 0.73 61 87.1 0.65 58 82.9
NAT2*5 Cambodia 0.32 14 51.9 0.38 8 29.6 Fair to moderate
Tanzania 0.47 37 52.9 0.53 28 40.0
NAT2*6 Cambodia 0.70 26 96.3 0.73 25 92.6 Substantial
Tanzania 0.74 62 88.6 0.71 62 88.6
NAT2*7 Cambodia 0.72 25 92.6 0.70 22 81.5 Substantial
Tanzania 0.75 55 78.6 0.67 49 70.0
NAT2*14 Cambodia 1.00 27 100.0 1.00 27 100.0 Substantial to almost
Tanzania 0.76 62 88.6 0.74 61 87.1 perfect
Data was acquired in 27 Cambodian and 70 Tanzanian malaria patients. κ indicates the kappa index. n is the number and % the percentage of 
samples with results for both techniques.
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SNP data gathered from sequencing and from microarray
analysis were compared. Kappa statistics was used as an
approach to the evaluation of agreement for the categori-
cal data obtained by the two methods. The kappa index
was calculated from contingency tables as follows κ = ((a
+ b) × (a + c) + (c + d) × (b + d))/(a + b + c + d)2
The kappa index was interpreted based on the criteria of
Landis and Koch [37]. Hardy-Weinberg equilibrium was
tested using the chi-square Hardy-Weinberg equilibrium
test calculator for bi-allelic markers of the Online Encyclo-
pedia for Genetic Epidemiology studies [38].
Ethical approval
All the applied protocols were approved by the ethics
committee of the two cantons of Basel (Ethikkommission
beider Basel, EKBB) and the responsible local authorities
(i.e. in Tanzania from the Institutional Review Board of
the Ifakara Health Institute and the National Institute for
Medical Research Review Board and in Cambodia from
the National Ethics Committee for Health Research).
Blood samples were collected following written informed
consent in the respective local language (Khmer or Swa-
hili) from the participants or their guardians.
Results
Agreement between results obtained from sequencing and
from the microarray on 18 SNPs within eight cyp isoen-
zyme genes and nat2 genes from 26 Cambodian and 70
Tanzanian malaria patients was tested. The results are
summarized in Table 4. For some SNPs agreement ranged
from substantial to almost perfect, whilst for other SNPs a
large variability from slight to substantial agreement was
found.
Where applicable, Chi-square Hardy-Weinberg equilib-
rium tests for the allele frequencies acquired by the micro-
array showed that most SNPs were significantly (P < 0.01)
out of equilibrium (Table 5). Exceptions were
CYP2D6*17 (1023C>T) (P = 0.50) for Tanzania after the
1st wash; CYP2C8*3 (P = 0.92), CYP2C9*3 (P = 0.92),
CYP2C9*5 (P = 0.92), CYP2D6*4 (P = 0.92) and
CYP3A5*3 (P = 0.16) after the 1st wash and CYP3A5*3 (P
= 0.01) and NAT2 (P = 0.07) after the 2nd wash for Cam-
bodia.
In contrast, most allele frequencies acquired by sequenc-
ing were found to be in Hardy-Weinberg equilibrium
(Table 6). However, in the Tanzanian study population
CYP2B6*5 and CYP2D6*4 and in the Cambodian study
population CYP2B6*5, CYP2C9*3, CYP2D6*10
(4180G>C), and CYP2D6*17 (2850C>T) were found not
to have Hardy-Weinberg proportions.
Discussion
Comparison of data generated by microarray analysis
with sequencing showed that the performance of the DNA
Table 5: Chi-square Hardy-Weinberg equilibrium tests for SNP data acquired by DNA microarray technology.
Cambodia Tanzania
1st wash 2nd wash 1st wash 2nd wash
SNP χ2 P χ2 P χ2 P χ2 P
CYP2A6*2 23.00 < 0.01 7.29 < 0.01 23.57 < 0.01 34.02 < 0.01
CYP2B6*5 N.A. N.A. 54.39 < 0.01 32.76 < 0.01
CYP2B6*6 N.A. N.A. 16.90 < 0.01 17.41 < 0.01
CYP2C8*3 0.01 0.92 N.A. 8.22 < 0.01 39.35 < 0.01
CYP2C9*3 0.01 0.92 N.A. 22.08 < 0.01 11.13 < 0.01
CYP2C9*5 0.01 0.92 N.A. 14.69 < 0.01 14.30 < 0.01
CYP2C19*3 N.A. N.A. 18.22 < 0.01 9.98 < 0.01
CYP2D6*4 0.01 0.92 N.A. 20.87 < 0.01 18.55 < 0.01
CYP2D6*10 (100C>T) 24.00 < 0.01 7.39 < 0.01 31.00 < 0.01 27.00 < 0.01
CYP2D6*10 (4180G>C) 13.67 < 0.01 N.A. 11.94 < 0.01 38.00 < 0.01
CYP2D6*17 (1023C>T) 11.90 < 0.01 7.00 < 0.01 0.45 0.5 35.34 < 0.01
CYP2D6*17 (2850C>T) 7.35 < 0.01 10.00 < 0.01 37.66 < 0.01 30.03 < 0.01
CYP3A4*1B N.A. N.A. N.A. 24.00 < 0.01
CYP3A5*3 1.98 0.16 6.39 0.01 13.36 < 0.01 18.74 < 0.01
N.A.T2*5 8.41 < 0.01 3.32 0.07 13.83 < 0.01 13.70 < 0.01
N.A.T2*6 N.A. N.A. 33.29 < 0.01 12.04 < 0.01
N.A.T2*7 9.97 < 0.01 8.63 < 0.01 30.21 < 0.01 24.82 < 0.01
N.A.T2*14 N.A. N.A. 32.08 < 0.01 19.30 < 0.01
χ2 indicates the result from the Hardy-Weinberg equilibrium test, P the one-tailed P-value, and N.A. that Chi-square could not be calculated 
because the allele frequency was either 0% or 100%.Page 6 of 9
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CYP2B6*5, CYP2C8*3, CYP2C9*3/*5, CYP2C19*3,
CYP2D6*4 and NAT2*6/*7/*14, agreement ranged from
substantial to almost perfect (kappa index between 0.61
and 1.00), whilst for other SNPs a large variability from
slight to substantial agreement (kappa index between
0.39 and 1.00) was found, e.g. CYP2D6*17 (2850C>T),
CYP3A4*1B and CYP3A5*3. No clear trend in rise or
decline of agreement between methods was visible from
the 1st to the 2nd wash of the slide and thus it remains
ambiguous whether repeated washing improves the per-
formance of the microarray. However, agreement tends to
be lower among the Cambodian samples. A possible
explanation is the strong dependence of kappa on true
prevalence of the SNPs [39] and the dissimilar distribu-
tion of the SNPs of interest in Cambodians and Tanza-
nians [40]. Furthermore, among most of these SNPs a
considerable number of patient samples failed to yield a
signal on the microarray (e.g. CYP2D6*17 (2850C>T) and
CYP CYP3A4*1B). The trend was clearly higher in samples
from Tanzania, which might also be due to a lower quality
of DNA arising from sub-optimal storage conditions after
blood withdrawal. Sequencing data agreed with pub-
lished reference sequences from public sources (Human
Cytochrome P450 (CYP) Allele Nomenclature Committee
[41]. The majority of samples genotyped by sequencing
was found to be in Hardy-Weinberg equilibrium (excep-
tions were CYP2B6*5 in Cambodians and CYP2D6*4 in
Tanzanians), proving that sampling was unbiased. The
cases where population data generated by microarray was
found not to be in Hardy-Weinberg proportion could be
attributed to the large number of patient samples that
failed to yield a signal on the microarray resulting in
smaller simple size.
Because cyps evolved out of a single ancestor [1,42], they
show very close sequence similarities, which in turn
makes it difficult to design gene specific primers, in partic-
ular extension primers that have to be designed at a
defined position. It, therefore, became almost impossible
to develop a single multiplex PCR and thus the microarray
method described here is time consuming and laborious.
This is in contrast to a similar microarray developed for
the analysis of drug resistance associated SNPs in P. falci-
parum genes that permits the simultaneous analysis of
many SNPs in hundreds of samples in a very short time
period (approximately 15 h for four 96-well plates) with
significantly reduced costs compared to other systems [5].
Furthermore, the costs of sequencing have decreased con-
siderably during the last years and this trend may well
continue. On the other hand, the costs of microarray rea-
gents (especially Cy3- and Cy5-labeled ddNTPs that are
used in three combinations) and glass slides for arraying
have increased and are unlikely to decrease over time. So
the costs for the microarray technology are not considera-
bly lower anymore and, therefore, overall costs of both
methods have become comparable.
While SNP analysis microarray has been successfully used
to analyse point mutations in drug resistance associated
genes in Plasmodium [5,43], it seems to fail with closely
related genes, such as the human cyp genes. For the latter,
sequencing appears to be a more reliable method.
Conclusion
Although microarray allows the simultaneous determina-
tion of many SNPs, the lack of robustness for the
described approach here prohibits its wide use in pharma-
cogenetics and sequencing occurs to be the more reliable
technique. With the availability of large sequencing capac-
ities worldwide, molecular-epidemiological studies using
sequencing for a limited number of SNPs in CYP genes in
a large population are feasible.
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Cy: Cyanine; CYP: Cytochrome P450; ddNTP: Dideoxy-
nucleotide; DNA: Deoxyribonucleic acid; dNTP: Deoxy-
nucleotide; EDTA: Ethylenediaminetetraacetic acid;
NAT2: N-acetyletransferase-2; PCR: Polymerase chain
reaction; PFCRT: Plasmodium falciparum chloroquine
resistance transporter; RFLP: Restriction fragment length
polymorphism; ROC: Receiver operating characteristic;
SAP: Shrimp alkaline phosphatise; SDS: Sodium dodecyl
Table 6: Chi-square Hardy-Weinberg equilibrium tests for SNP 
data acquired by sequencing.
Cambodia Tanzania
SNP χ2 P χ2 P
CYP2A6*2 N.A. N.A.
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calculated because the allele frequency was either 0% or 100%.Page 7 of 9
(page number not for citation purposes)
Malaria Journal 2009, 8:285 http://www.malariajournal.com/content/8/1/285sulphate; SNP: Single nucleotide polymorphism; SSC:
Standard saline citrate; TE: Tris-EDTA
Competing interests
The authors declare that they have no competing interests.
Support for this work was provided by grant No 320000-
112479 from the Swiss National Science Foundation.
Authors' contributions
EMH and SL were involved in microarray technology
development and validation, data acquisition and analy-
sis, and writing of the manuscript. WQ has developed the
programme for the ROC analysis. FA was involved in the
technology development. BG was involved in the overall
pharmacogenetic project design and supervision. HPB
was involved in the project design, technology develop-
ment and in writing the manuscript
Acknowledgements
We would like to thank the patients who participated in the study and all 
the people involved in sample collection and we are grateful to the staff of 
the Center for Integrative Genomics in particular to Keith Hershman, 
Jérôme Thomas and Johann Weber for spotting the microarrays.
References
1. Ingelman-Sundberg M: The human genome project and novel
aspects of cytochrome P450 research.  Toxicol Appl Pharmacol
2005, 207(2 Suppl):52-56.
2. Ingelman-Sundberg M, Rodriguez-Antona C: Pharmacogenetics of
drug-metabolizing enzymes: implications for a safer and
more effective drug therapy.  Philos Trans R Soc Lond B Biol Sci
2005, 360(1460):1563-1570.
3. Sobrino B, Brión M, Carracedo A: SNPs in forensic genetics: a
review on SNP typing methodologies.  Forensic Sci Int 2005,
154(2-3):181-94.
4. Sobrino B, Carracedo A: SNP typing in forensic genetics: a
review.  Methods Mol Biol 2005, 297:107-26.
5. Crameri A, Marfurt J, Mugittu K, Maire N, Regös A, Coppee J, Sis-
meiro O, Burki R, Huber E, Laubscher D, Puijalon O, Genton B,
Felger I, Beck HP: Rapid microarray-based method for moni-
toring of all currently known single-nucleotide polymor-
phisms associated with parasite resistance to antimalaria
drugs.  J Clin Microbiol 2007, 45(11):3685-3691.
6. Miller J, Trepanier L: Inhibition by atovaquone of CYP2C9-
mediated sulphamethoxazole hydroxylamine formation.  Eur
J Clin Pharmacol 2002, 58(1):69-72.
7. Li X, Björkman A, Andersson T, Ridderström M, Masimirembwa C:
Amodiaquine clearance and its metabolism to N-desethyl-
amodiaquine is mediated by CYP2C8: a new high affinity and
turnover enzyme-specific probe substrate.  J Pharmacol Exp
Ther 2002, 300(2):399-407.
8. Khoo S, Back D, Winstanley P: The potential for interactions
between antimalarial and antiretroviral drugs.  AIDS 2005,
19(10):995-1005.
9. White N, van Vugt M, Ezzet F: Clinical pharmacokinetics and
pharmacodynamics and pharmacodynamics of artemether-
lumefantrine.  Clin Pharmacokinet 1999, 37(2):105-125.
10. Svensson U, Ashton M: Identification of the human cytochrome
P450 enzymes involved in the in vitro metabolism of artem-
isinin.  Br J Clin Pharmacol 1999, 48(4):528-535.
11. Giao P, de Vries P: Pharmacokinetic interactions of antimalar-
ial agents.  Clin Pharmacokinet 2001, 40(5):343-373.
12. Li X, Björkman A, Andersson T, Gustafsson L, Masimirembwa C:
Identification of human cytochrome P(450)s that metabolise
anti-parasitic drugs and predictions of in vivo drug hepatic
clearance from in vitro data.  Eur J Clin Pharmacol 2003, 59(5-
6):429-442.
13. Grace J, Aguilar A, Trotman K, Peggins J, Brewer T: Metabolism of
beta-arteether to dihydroqinghaosu by human liver micro-
somes and recombinant cytochrome P450.  Drug Metab Dispos
1998, 26(4):313-317.
14. Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet A, Duc-
harme J: In vitro metabolism of chloroquine: identification of
CYP2C8, CYP3A4, and CYP2D6 as the main isoforms cata-
lyzing N-desethylchloroquine formation.  Drug Metab Dispos
2003, 31(6):748-754.
15. Kim K, Park J, Lee J, Lim S: Cytochrome P450 2C8 and CYP3A4/
5 are involved in chloroquine metabolism in human liver
microsomes.  Arch Pharm Res 2003, 26(8):631-637.
16. Halliday R, Jones B, Smith D, Kitteringham N, Park B: An investiga-
tion of the interaction between halofantrine, CYP2D6 and
CYP3A4: studies with human liver microsomes and heterol-
ogous enzyme expression systems.  Br J Clin Pharmacol 1995,
40(4):369-378.
17. Fontaine F, de Sousa G, Burcham P, Duchêne P, Rahmani R: Role of
cytochrome P450 3A in the metabolism of mefloquine in
human and animal hepatocytes.  Life Sci 2000,
66(22):2193-2212.
18. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sun-
bhanich M: Ketoconazole increases plasma concentrations of
antimalarial mefloquine in healthy human volunteers.  J Clin
Pharm Ther 2005, 30(3):285-290.
19. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhan-
ich M: Effect of rifampin on plasma concentrations of meflo-
quine in healthy volunteers.  J Pharm Pharmacol 2000,
52(10):1265-1269.
20. Kaneko A, Bergqvist Y, Taleo G, Kobayakawa T, Ishizaki T, Björkman
A: Proguanil disposition and toxicity in malaria patients from
Vanuatu with high frequencies of CYP2C19 mutations.  Phar-
macogenetics 1999, 9(3):317-326.
21. Skjelbo E, Mutabingwa T, Bygbjerg I, Nielsen K, Gram L, Brøosen K:
Chloroguanide metabolism in relation to the efficacy in
malaria prophylaxis and the S-mephenytoin oxidation in
Tanzanians.  Clin Pharmacol Ther 1996, 59(3):304-311.
22. Mirghani R, Yasar U, Zheng T, Cook J, Gustafsson L, Tybring G, Eric-
sson O: Enzyme kinetics for the formation of 3-hydroxyqui-
nine and three new metabolites of quinine in vitro; 3-
hydroxylation by CYP3A4 is indeed the major metabolic
pathway.  Drug Metab Dispos 2002, 30(12):1368-1371.
23. Mirghani R, Hellgren U, Westerberg P, Ericsson O, Bertilsson L, Gus-
tafsson L: The roles of cytochrome P450 3A4 and 1A2 in the
3-hydroxylation of quinine in vivo.  Clin Pharmacol Ther 1999,
66(5):454-460.
24. Zhang H, Coville P, Walker R, Miners J, Birkett D, Wanwimolruk S:
Evidence for involvement of human CYP3A in the 3-hydrox-
ylation of quinine.  Br J Clin Pharmacol 1997, 43(3):245-252.
25. Barraviera B, Pereira P, Machado J, de Souza M, Lima C, Curi P,
Mendes R, Meira D: Isoniazid acetylating phenotype in patients
with paracoccidioidomycosis and its relationship with serum
sulfadoxin levels, glucose-6-phosphate dehydrogenase and
glutathione reductase activities.  Rev Soc Bras Med Trop
24(2):111-114.
26. Alfirevic A, Stalford A, Vilar F, Wilkins E, Park B, Pirmohamed M:
Slow acetylator phenotype and genotype in HIV-positive
patients with sulphamethoxazole hypersensitivity.  Br J Clin
Pharmacol 2003, 55(2):158-165.
27. Daly A: Pharmacogenetics of the cytochromes P450.  Curr Top
Med Chem 2004, 4(16):1733-1744.
28. Gil J: Amodiaquine pharmacogenetics.  Pharmacogenomics 2008,
9(10):1385-1390.
29. Mehlotra R, Henry-Halldin C, Zimmerman P: Application of phar-
macogenomics to malaria: a holistic approach for successful
chemotherapy.  Pharmacogenomics 2009, 10(3):435-449.
30. Tarning J, Bergqvist Y, Day N, Bergquist J, Arvidsson B, White N, Ash-
ton M, Lindegårdh N: Characterization of human urinary
metabolites of the antimalarial piperaquine.  Drug Metab Dis-
pos 2006, 34(12):2011-2019.
31. Klinker H, Langmann P, Richter E: Plasma pyrimethamine con-
centrations during long-term treatment for cerebral toxo-
plasmosis in patients with AIDS.  Antimicrob Agents Chemother
1996, 40(7):1623-1627.
32. Cavallito J, Nichol C, Brenckman WJ, Deangelis R, Stickney D, Sim-
mons W, Sigel C: Lipid-soluble inhibitors of dihydrofolatePage 8 of 9
(page number not for citation purposes)
Malaria Journal 2009, 8:285 http://www.malariajournal.com/content/8/1/285Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
reductase. I. Kinetics, tissue distribution, and extent of
metabolism of pyrimethamine, metoprine, and etoprine in
the rat, dog, and man.  Drug Metab Dispos 6(3):329-337.
33. Lee J, Son J, Chung S, Lee E, Kim D: In vitro and in vivo metabo-
lism of pyronaridine characterized by low-energy collision-
induced dissociation mass spectrometry with electrospray
ionization.  J Mass Spectrom 2004, 39(9):1036-1043.
34. Rolan P, Mercer A, Tate E, Benjamin I, Posner J: Disposition of
atovaquone in humans.  Antimicrob Agents Chemother 1997,
41(6):1319-1321.
35. Agwuh K, MacGowan A: Pharmacokinetics and pharmacody-
namics of the tetracyclines including glycylcyclines.  J Antimi-
crob Chemother 2006, 58(2):256-265.
36. Kestler H: ROC with confidence - a Perl program for receiver
operator characteristic curves.  Comput Methods Programs Biomed
2001, 64(2):133-136.
37. Landis J, Koch G: The measurement of observer agreement for
categorical data.  Biometrics 1977, 33(1):159-174.
38. Online Encyclopedia for Genetic Epidemiology studies
[http://www.oege.org/]
39. Thompson W, Walter S: A reappraisal of the kappa coefficient.
J Clin Epidemiol 1988, 41(10):949-958.
40. Vach W: The dependence of Cohen's kappa on the prevalence
does not matter.  J Clin Epidemiol 2005, 58(7):655-661.
41. Home Page of the Human Cytochrome P450 (CYP) Allele
Nomenclature Committee   [http://www.cypalleles.ki.se/]
42. Lewis D, Watson E, Lake B: Evolution of the cytochrome P450
superfamily: sequence alignments and pharmacogenetics.
Mutat Res 1998, 410(3):245-270.
43. Ibrahim M, Steenkeste N, Khim N, Adam H, Konaté L, Coppée J,
Ariey F, Duchemin J: Field-based evidence of fast and global
increase of Plasmodium falciparum drug-resistance by DNA-
microarrays and PCR/RFLP in Niger.  Malar J 2009, 8:32.
44. Consensus Human Arylamine N-Acetyltransferase Gene
Nomenclature   [http://louisville.edu/medschool/pharmacology/
NAT.html]Page 9 of 9
(page number not for citation purposes)
